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Summary
Background: Cibenzoline (CBZ), a class I antiarrhythmic drug, has been widely used
to maintain sinus rhythm in patients with paroxysmal atrial ﬁbrillation (P-AF). This
agent has an anticholinergic action and will become the drug of ﬁrst choice for
vagally mediated P-AF. We assessed its efﬁcacy quantitatively by analyzing the
frequency-domain heart rate variability (FD-HRV) of the Holter electrocardiogram
(ECG) in patients with vagal P-AF.
Methods: We enrolled 65 consecutive patients with vagal P-AF, but 31 patients were
excluded because of the occurrence of signiﬁcant arrhythmias during the 24-h Holter
recordings. Accordingly, CBZ was administered to the remaining 34 patients. After
administration, a Holter ECG recording was made again. High frequency (HF) com-
ponents, i.e., vagal tone index, on the FD-HRV analysis from 00:00 h to 06:00 h were
used for assessment. In 14 patients, the treatment was changed to disopyramide
(DSP) and the same analyses were performed.
Results: In two patients, the FD-HRV analysis was not utilized after administration.
Finally, 32 patients were available for evaluation. CBZ was considered effective
for vagal P-AF in 24 patients (75%). After administration, the HF component lev-
els decreased (1589± 795ms2 vs. 850± 524ms2, p < 0.0001). Comparison of the
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Antiarrhythmic drug and vaga
component levels after drug administration is useful for a quantitative assessment of
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ulation in two patients (6%), aspirin in ﬁve (15%),
-blockers for inhibition of heart rate in two (6%),
and verapamil in one (6%).anticholinergic action.
© 2009 Japanese Colleg
reserved.
Introduction
Paroxysmal atrial ﬁbrillation (P-AF) is one of the
most common arrhythmias seen in daily practice.
In general, P-AF is not an arrhythmia with a poor
prognosis, particularly in patients with normal car-
diac function, but it is an arrhythmia that may
lower quality of life by causing certain symp-
toms such as palpitations, or occasionally lead to
serious complications such as cerebral infarction.
For the treatment of P-AF, either pharmacologi-
cal treatment or catheter ablation is used, with
the former treatment being carried out in most
patients.
P-AFs are classiﬁed into three types depending
on the pattern of onset: (1) vagal type; (2) sympa-
thetic type and (3) mixed type [1—3]. Among these
types, with respect to vagal P-AF, as stated in the
guidelines in America, Europe, and Japan [1,2] class
I antiarrhythmic drugs such as cibenzoline (CBZ) or
disopyramide (DSP) should be the pharmacological
treatment of ﬁrst choice to inhibit P-AF.
One method used for quantitative assessment of
vagal nerve activity is the frequency-domain (FD)
method [4]. This method, which measures heart
rate variability (HRV) by means of a 24-h Holter
electrocardiogram (ECG), is used in clinical practice
[5,6]. High frequency (HF) components obtained
from the FD-HRV analyses are known to accurately
reﬂect vagal nerve activity [4—6].
The purpose of the present study was to evaluate
quantitatively the effect of CBZ on vagal P-AF using
FD-HRV analyses with Holter ECG. In some patients
in whom the treatment could be changed from CBZ
to DSP, the anticholinergic actions of both drugs
were compared.
MethodsPatient enrollment
Sixty-ﬁve consecutive patients with vagal P-AF were
enrolled at Kyorin University Hospital from January
m
c
eCardiology. Published by Elsevier Ireland Ltd. All rights
005 to August 2008. Patients with P-AF of sym-
athetic or mixed type were excluded from the
tudy. These deﬁnitions of P-AF were made by a
ymptom logbook recorded by the patient [7]. They
nitially sought medical consultation for subjec-
ive symptoms such as palpitations. These patients
ad no underlying heart diseases, endocrine disor-
ers including thyroidal dysfunction, and/or other
athological conditions such as anemia, indicating
one AF. Vagal P-AF was deﬁned as AF that initiated
t nighttime, at rest, and/or after taking meals,
nd which terminated spontaneously within 24 h
fter onset. All patients desired drug treatment and
ad not received antiarrhythmic drugs for at least
month or more prior to their enrollment. Patients
ith implanted pacemakers or a medical history
f invasive treatments such as catheter ablation
ere not included. Among all the patients, a P-AF
pisode was recorded two or more times within 1
onth prior to their enrollment.
When the 24-h Holter ECG was performed with-
ut any antiarrhythmic drug treatment in all 65
atients, P-AFs or atrial premature contractions
APCs) >10 beats/h were found sporadically during
ecording in 31 patients. Since HRV analysis is used
o measure the interval between normal beats,
hen such arrhythmias occur during recording, an
ssessment using FD-HRV analysis becomes impossi-
le. Thus, those 31 patients were excluded from the
tudy. As a result, the remaining 34 patients (mean
ge 58± 16 years, 28 males and 6 females) were
valuated in this study (Table 1). The average heart
ate at rest was 72± 17 beats/min. On echocardio-
raphy, the left atrial diameter was found to be
6± 2mm and the left ventricular ejection fraction
as 63± 5%. These levels were all within normal
anges. Concomitant drugs were warfarin anticoag-lly mediated AF 87
pre-administration HF component levels between the CBZ-responsive group and
the CBZ-non-responsive group showed higher levels in the CBZ-responsive group
(1766± 758ms2 vs. 1058± 690ms2, p = 0.026). Although no signiﬁcant difference in
the reduction of the HF component levels was found between CBZ and DSP, DSP had
anticholinergic side effects in two patients (14%).
Conclusions: In vagal P-AF patients, larger HF components on the FD-HRV analysis
could be a hallmark of the antiarrhythmic action of CBZ. The reduction in the HFThe protocol was approved by the ethical com-
ittee of Kyorin University Hospital. Informed
onsent was obtained from all patients prior to
nrollment into the study.
88
Table 1 Clinical background of the study patients.
Number of patients 34
Age (years) 58± 16
Men 28 (82%)
Underlying heart diseases 0 (0%)
Lone atrial ﬁbrillation 34 (100%)
Heart rate at rest (beats/min) 72± 17
Left atrial diameter (mm) 36± 2
Left ventricular ejection fraction (%) 63± 5
Thromboprophylaxis drugs
Warfarin 2 (6%)
Aspirin 5 (15%)
Rate control drugs
-Blockers 2 (6%)
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FD-HRV analyses with 24-h Holter ECG
Before drug administration, a 24-h Holter ECG was
performed in all patients. The ECG wave patterns
obtained were analyzed for HRV by an ECG ana-
lyzer (SCM-6000, Fukuda Denshi Co., Ltd., Tokyo,
Japan). Although there are several methods used
for HRV analysis including the time-domain and
FD methods, the FD method, which is capable of
reﬂecting short-term changes in autonomic ner-
vous system activity [4], was used in this study.
In the FD method, although the HF component
(0.15—0.40Hz), low frequency (LF) component
(0.04—0.15Hz), and LF/HF ratio are measured
automatically, in this study, only the HF compo-
nent levels, which are a reliable way of assessing
vagal nerve activity, were used. To facilitate the
quantitative assessment of vagal nerve activity, the
mean HF component levels from 00:00 h (midnight)
to 06:00 h (early morning) [8], when vagal nerve
activity is considered to be higher than at other
times, were used in this study.
The same analyses were performed after drug
administration. When arrhythmias such as P-AF or
APC occurred during the recording of the 24-h
Holter ECG after drug administration, the Holter
ECG was repeated as FD-HRV analysis of such
recordings was considered inappropriate.
Administration of antiarrhythmic drugs
After the recording of the 24-h Holter ECG, CBZ
was administered orally at a dose of 300mg/day.
However, for patients with kidney dysfunction
(glomerular ﬁltration rate <40mL/min/1.73m2)
and elderly patients (>80 years), the dose was
200mg/day. After a 4-week administration period,
T
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s CBZ was being administered, the Holter ECG was
erformed again.
In 14 of the 34 patients, after the effect of
BZ was evaluated and 1 week had elapsed from
rug discontinuation, the treatment was changed
o DSP, a class I antiarrhythmic drug with simi-
ar anticholinergic action to CBZ. After 4 weeks
f oral administration of DSP, a 24-h Holter ECG
as recorded. The dose of DSP was 300mg/day,
nd 200mg/day for patients with renal dysfunction
nd for elderly patients. The anticholinergic actions
ere compared between both drugs.
valuation of drug efﬁcacy
ecause all the subjects in this study were P-AF
atients, drug efﬁcacy was evaluated based on
he presence/absence or disappearance of symp-
oms. To conﬁrm the disappearance of symptoms,
atients recorded their symptoms in a notebook.
he patients were instructed to record whether
ymptoms were present or absent after drug admin-
stration, and if they were present, to record daily
he nature, frequency, and duration of symptoms.
hen, whether the symptoms induced by P-AF dis-
ppeared was evaluated.
In addition, the absence of P-AF was conﬁrmed
y 24-h Holter ECG after drug administration. Even
n patients in whom symptoms had apparently dis-
ppeared, when P-AF appeared, even temporarily,
s detected by the 24-h Holter ECG, the drug was
valuated as being not effective.
tatistical tests
he real numbers in the text are expressed as the
ean level± standard deviation. Comparison of the
F component levels between both drugs assessed
n the same patient before and after drug admin-
stration was performed by Student’s paired t-test.
omparison of the HF component levels between
he groups in which the drug was effective and
ot effective was performed by Student’s unpaired
-test. A level of p < 0.05 was considered to be sig-
iﬁcant in both tests.
esults
rug efﬁcacyhe dose of CBZ was 300mg/day in 31 patients
91%) and 200mg/day in the remaining 3 patients.
n 2 of the 34 patients who received CBZ, because
PCs appeared sporadically during the two record-
Antiarrhythmic drug and vagally mediated AF 89
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cigure 1 The effects of cibenzoline (CBZ) and disopy-
amide (DSP) on vagally mediated paroxysmal atrial
brillation (P-AF).
ngs of the Holter ECG, the FD-HRV could not be
nalyzed and these patients were excluded from
ssessment. Accordingly, the effect of CBZ on HF
omponent levels was assessed in 32 patients. The
dministered CBZ brought about complete elimina-
ion of the symptoms without any P-AF detected by
he 24-h Holter ECG in 24 of the 32 patients (75%)
Fig. 1A). These patients were classiﬁed into the
BZ-responsive group and the remaining patients
nto the CBZ-non-responsive group. During the
D
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igure 3 Actual frequency-domain heart rate variability (FD
omponent levels decreased after oral administration of cibeigure 2 Comparison of high frequency (HF) component
evels before and after the administration of cibenzoline
CBZ) for vagal paroxysmal atrial ﬁbrillation (P-AF).
ral administration of CBZ, no side effects such as
nticholinergic effects on organs other than the
eart were found in any of the patients.
In 14 patients whose treatment was changed toSP, FD-HRV analyses could be carried out on all
atients. The dose was 300mg/day in 13 patients
93%) and 200mg/day in 1 (7%). DSP was effective
n 10 of the 14 patients (71%) (Fig. 1B). As for side
-HRV) analyses in a patient whose high frequency (HF)
nzoline (CBZ). LF, low frequency.
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Figure 4 Comparison of high frequency (HF) compo- Figure 5 Comparison of the effects of cibenzoline (CBZ)
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mnent levels before drug administration in the cibenzoline
(CBZ)-responsive group and the CBZ-non-responsive
group.
effects, with DSP, anticholinergic effects on organs
other than the heart, such as a dry mouth and fre-
quent urination, which do not appear with CBZ,
were reported in 2 of the 14 patients (14%). Con-
sequently, the change from CBZ to DSP resulted in
termination of treatment in more patients than was
the case with CBZ, owing to substantial side effects.
FD-HRV analyses pre- and post-drug state
The mean level of the HF components from
00:00 h to 06:00 h according to FD-HRV analy-
ses performed before drug administration was
1589± 795ms2. After administration of CBZ, the
mean level decreased to 850± 524ms2, indicat-
ing that CBZ decreased HF component levels
signiﬁcantly (p < 0.0001) (Fig. 2). Fig. 3 shows
actual FD-HRV analyses of a patient in which
CBZ decreased HF component levels. When the
HF component levels before drug administra-
tion were compared between the CBZ-responsive
group (n = 24) and the CBZ-non-responsive group
(n = 8), the CBZ-responsive group had a signiﬁ-
cantly higher level than the CBZ-non-responsive
group (1766± 758ms2 vs. 1058± 690ms2, respec-
tively, p = 0.026) (Fig. 4). On the other hand, after
drug administration, no signiﬁcant difference was
found in the HF component levels between the
CBZ-responsive group and the CBZ-non-responsive
group (864± 510ms2 vs. 810± 599ms2, respec-
tively, p =N.S.). When the reduction levels for
the HF components were calculated, they were
−902±−648ms2 in the CBZ-responsive group and
−248±−369ms2 in the CBZ-non-responsive group,
with the difference being signiﬁcant (p = 0.011).
The mean level of the HF components from
00:00 h to 06:00 h after administration of DSP
v
a
[
tnd disopyramide (DSP) on high frequency (HF) compo-
ent levels.
as 989± 528ms2. Similar to CBZ, DSP decreased
he HF component levels signiﬁcantly (p = 0.002).
hen the HF component levels and reduction lev-
ls before drug administration were compared
etween the DSP-responsive group and the DSP-
on-responsive group, no signiﬁcant difference
as found. However, the levels in the DSP-
esponsive group tended to be higher than in
he DSP-non-responsive group (1731± 806ms2 vs.
490± 485ms2, respectively) and the reduction
evels of HF components in the former group
lso tended to be higher (−834±−531ms2 vs.
270±−764ms2, respectively).
omparison of HF component levels
etween CBZ and DSP
o compare the effects on the HF component levels
etween CBZ and DSP, the reduction levels of the
F components were compared in the 14 patients
ho received both drugs. No signiﬁcant difference
as found for either drug (Fig. 5).
iscussion
t is known that P-AF is likely to occur in conjunc-
ion with basic underlying heart diseases such as
alvular disorders, ischemic heart diseases, car-
iomyopathies, and hypertensive heart disease.
owever, P-AF may occur in the normal heart, and
ay be induced by modulation of autonomic ner-
ous functions. Thus, autonomic nervous activity is
lso an important factor in the occurrence of P-AF
1,2]. In fact, there have been many reports stating
hat  receptor and muscarinic receptor antago-
An
a
b
t
i
a
a
W
o
r
s
y
i
T
y
p
n
a
t
a
p
t
h
n
h
t
i
w
a
d
h
c
a
I
m
c
I
a
c
c
t
f
o
w
m
c
t
t
ﬁ
r
a
n
[
H
C
a
r
g
d
y
t
d
t
a
p
p
o
p
o
w
t
c
S
T
e
m
n
i
c
t
p
o
t
t
P
s
u
a
(
t
a
t
e
a
t
Cntiarrhythmic drug and vagally mediated AF
ists are effective therapy for P-AF induced by
utonomic nervous activity [7,9,10]. P-AFs induced
y autonomic nervous activity are classiﬁed into
wo types: vagal P-AF, which is likely to appear
n association with sleep, rest, and after meals
nd sympathetic P-AF, which is likely to appear in
ssociation with exercise, tension, and stress [4].
hen P-AFs are classiﬁed according to the time of
nset, either nighttime or daytime, the former cor-
esponds to the vagal type and the latter to the
ympathetic type [5]. In younger patients (aged 60
ears or less) without underlying heart diseases, it
s reported that vagal P-AFs occur more often [11].
he mean age of the patients in this study was 58
ears, which is relatively young, in keeping with
revious studies.
One mechanism by which the tensional vagal
erves induce P-AFs is assumed to be as follows:
cetylcholine is released from the terminal parts of
he vagal nerves, binds to M2 muscarinic receptors,
nd then activates the IK,ACh channels through G1
roteins to reduce the action potential duration of
he atrial myocardium [12,13]. Many experiments
ave demonstrated that stimulation of the vagal
erves induces a typical P-AF [14,15]. On the other
and, it has been demonstrated that the elimina-
ion of the inﬂuence of the vagal nerves does not
nduce P-AF [16].
CBZ and DSP are class I antiarrhythmic drugs
ith anticholinergic actions. However, the mech-
nisms of the anticholinergic actions of both
rugs are somewhat different. Although both drugs
ave antagonistic actions against the M2 mus-
arinic receptors of the atrial myocardium, CBZ
lso directly blocks the IK,ACh channels [17]. The
K,ACh channels do not exist in the ventricular
yocardium, but are abundant in the sinus node
ells and atrial myocardium. In the atrium, the
K,ACh plays an important role in determining the
trial action potential duration [13]. If the IK,ACh
hannels are directly blocked in addition to M2 mus-
arinic receptors, theoretically, it can be inferred
hat the inhibitory action of CBZ on the vagal nerve
unctions in P-AF patients is more potent than that
f DSP. Compared with DSP, CBZ is reported to have
eaker anticholinergic actions on the brain (M1
uscarinic receptors), and glands and smooth mus-
le (M3 muscarinic receptors) other than those of
he heart [18], and is thus recommended in order
o reduce side effects.
In this study, the HF component levels identi-
ed by the FD-HRV analyses were used as indices to
eﬂect vagal nerve activity. These component levels
re the indices that most accurately reﬂect vagal
erve activity among the many HRV analysis indices
4—6]. The results of this study indicate that the
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F component levels decreased in patients in whom
BZ was effective. The HF component levels before
dministration were signiﬁcantly higher in the CBZ-
esponsive patients than in the CBZ-non-responsive
roup. In considering indications for antiarrhythmic
rugs with anticholinergic action, the FD-HRV anal-
ses were considered useful. Another advantage is
hat the FD-HRV analyses allow the effects of these
rugs on vagal nerve activity to be evaluated quan-
itatively.
In this study, after administration of DSP, FD-HRV
nalyses were performed and the results were com-
ared with those of CBZ. Because the number of
atients was low, the superiority of CBZ in terms
f anticholinergic action on the heart could not be
roved. However, anticholinergic side effects on
rgans other than the heart which did not occur
ith CBZ occurred in 14% of patients taking DSP. In
erms of reducing or avoiding side effects, CBZ is
onsidered to be superior.
tudy limitations
his study had a number of limitations. First, the
ffects of the antiarrhythmic drugs were evaluated
ainly based on the disappearance of symptoms,
ot by a prolonged period of continuous ECG record-
ng. Thus, it may be difﬁcult to state that P-AF
ould be inhibited completely [19]. However, in
his study, because the subjects were only those
atients with clear P-AF symptoms, the reliability
f the results is considered to be high.
Second, patients with sympathetic P-AF or mixed
ype P-AF were not enrolled and not used as a con-
rol group. To state that CBZ is effective for vagal
-AF, it may be necessary to perform controlled
tudies.
The third issue is that the quantitative eval-
ation of the HF component levels by FD-HRV
nalyses was conducted within a limited period
00:00—06:00 h). Because there are periods during
he day when vagal nerve activity increases, such
s after meals or at rest, measurements at other
imes might be necessary. However, as the patients
nrolled in this study had P-AF episodes at night,
n analysis limited to the speciﬁc period chosen for
his study appears to be appropriate.
onclusionshe HF component levels obtained from FD-HRV
nalyses of Holter ECGs were useful as indices to
uantitatively assess the effects of antiarrhythmic
rugs with anticholinergic action. CBZ was shown
[[
[
[
[
[
[
[
[
vasc Pharmacol 1999;34:53—9.92
to have marked antiarrhythmic effects on patients
with symptomatic lone P-AF occurring at night. It
was also found that CBZ is less likely to have anti-
cholinergic actions on organs other than the heart,
compared to DSP.
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